In humans, the systemic treatment with tocilizumab, the blocking anti-IL-6R antibody approved for treatment of rheumatoid arthritis, has also been shown to increase the risk to respiratory virus infection (64). The gene discussed is IL6R; the disease is rheumatoid arthritis.